Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 5/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.50 |
| ▸ | SCN4A | P35499 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.40 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.40 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.40 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.40 |
| ▸ | BCL2 | P10415 | 2/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5962907 | 0.87 | SCN4A (0.49) | SCN9ASCN4AKMT2A | |
| SCHEMBL725497 | 0.86 | CYP2C9 (0.53) | SCN9ACYP2C9GAAALDH1A1KMT2A | |
| SCHEMBL6531865 | 0.83 | SCN9A (0.51) | SCN9ACYP2C9GAAALDH1A1KMT2A | |
| SCHEMBL28088814 | 0.82 | ALDH1A1 (0.51) | SCN9APARP10GAAALDH1A1KMT2A | |
| SCHEMBL5962973 | 0.80 | NPC1 (0.50) | SCN9AAPPGAAALDH1A1KMT2A | |
| SCHEMBL168402 | 0.76 | KMT2A (0.54) | SCN9AMGLLALDH1A1KMT2A | |
| SCHEMBL30078274 | 0.76 | ALDH1A1 (0.50) | SCN9AALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL5963146 | 0.75 | SCN9A (0.57) | SCN9ASCN4A | |
| SCHEMBL14247709 | 0.74 | SCN9A (0.42) | SCN9ACYP2C9ALDH1A1SMN1; SMN2 | |
| SCHEMBL30231293 | 0.74 | PARP10 (0.45) | SCN9APARP10SCN4ACTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1292577-B1 | ARYL SUBSTITUTED PYRAZOLES, TRIAZOLES AND TETRAZOLES AS SODIUM CHANNEL BLOCKER | EURO CELTIQUE SA (LU) | 2012-10-24 | — | — | EP | claimed |
| CN-1321112-C | Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker | EURO CELTIQUE SA (LU) | 2007-06-13 | — | — | CN | claimed |
| EP-1292577-B1 | ARYL SUBSTITUTED PYRAZOLES, TRIAZOLES AND TETRAZOLES AS SODIUM CHANNEL BLOCKER | EURO CELTIQUE SA (LU) | 2012-10-24 | — | — | EP | disclosed |
| EP-1292577-B1 | ARYL SUBSTITUTED PYRAZOLES, TRIAZOLES AND TETRAZOLES AS SODIUM CHANNEL BLOCKER | EURO CELTIQUE SA (LU) | 2012-10-24 | — | — | EP | disclosed |
| CN-1321112-C | Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker | EURO CELTIQUE SA (LU) | 2007-06-13 | — | — | CN | disclosed |
| US-7078426-B2 | Aryl substituted pyrazoles, triazoles, and tetrazoles, and the use thereof | EURO-CELTIQUE S.A. (LU) | 2006-07-18 | — | — | US | disclosed |
| US-6919363-B2 | Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof | EURO-CELTIQUE S.A. (LU) | 2005-07-19 | — | — | US | disclosed |
| US-20040002523-A1 | Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof | EURO-CELTIQUE S.A. | 2004-01-01 | — | — | US | disclosed |
| CN-1422257-A | Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker | EURO CELTIQUE SA (LU) | 2003-06-04 | — | — | CN | disclosed |
| EP-1292577-A2 | ARYL SUBSTITUTED PYRAZOLES, TRIAZOLES AND TETRAZOLES AS SODIUM CHANNEL BLOCKER | Euro-Celtique S.A. (LU) | 2003-03-19 | — | — | EP | disclosed |
| US-20020006947-A1 | Aryl substituted pyrazoles, triazoles, and tetrazoles, and the use thereof | PURDUE PHARMA L.P. | 2002-01-17 | — | — | US | disclosed |
| WO-2001072714-A2 | ARYL SUBSTITUTED PYRAZOLES, TRIAZOLES AND TETRAZOLES AS SODIUM CHANNEL BLOCKER | EURO-CELTIQUE S.A. (LU) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002523-A1 | Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof | CACNA1I, GRIK5, SOD1 | SCN9A 318/4885PARP10 4620/4885SCN4A 529/4885 |
| US-20020006947-A1 | Aryl substituted pyrazoles, triazoles, and tetrazoles, and the use thereof | GRIK5, CACNA1I, SOD1 | SCN9A 349/4885PARP10 4582/4885SCN4A 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.